FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366824059> ?p ?o ?g. }

• W4366824059 endingPage "1447" @default.
• W4366824059 startingPage "1437" @default.
• W4366824059 abstract "Tau plays a key role in Alzheimer's disease (AD) pathophysiology, and accumulating evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT expression with a tau-targeting antisense oligonucleotide (MAPTRx) and reduce tau levels in patients with mild AD. A randomized, double-blind, placebo-controlled, multiple-ascending dose phase 1b trial evaluated the safety, pharmacokinetics and target engagement of MAPTRx. Four ascending dose cohorts were enrolled sequentially and randomized 3:1 to intrathecal bolus administrations of MAPTRx or placebo every 4 or 12 weeks during the 13-week treatment period, followed by a 23 week post-treatment period. The primary endpoint was safety. The secondary endpoint was MAPTRx pharmacokinetics in cerebrospinal fluid (CSF). The prespecified key exploratory outcome was CSF total-tau protein concentration. Forty-six patients enrolled in the trial, of whom 34 were randomized to MAPTRx and 12 to placebo. Adverse events were reported in 94% of MAPTRx-treated patients and 75% of placebo-treated patients; all were mild or moderate. No serious adverse events were reported in MAPTRx-treated patients. Dose-dependent reduction in the CSF total-tau concentration was observed with greater than 50% mean reduction from baseline at 24 weeks post-last dose in the 60 mg (four doses) and 115 mg (two doses) MAPTRx groups. Clinicaltrials.gov registration number: NCT03186989 ." @default.
• W4366824059 created "2023-04-25" @default.
• W4366824059 creator A5005408821 @default.
• W4366824059 creator A5008484351 @default.
• W4366824059 creator A5009098620 @default.
• W4366824059 creator A5009940057 @default.
• W4366824059 creator A5011997502 @default.
• W4366824059 creator A5014420021 @default.
• W4366824059 creator A5023646369 @default.
• W4366824059 creator A5027033208 @default.
• W4366824059 creator A5034946822 @default.
• W4366824059 creator A5038851564 @default.
• W4366824059 creator A5040948544 @default.
• W4366824059 creator A5041113915 @default.
• W4366824059 creator A5042241854 @default.
• W4366824059 creator A5046921947 @default.
• W4366824059 creator A5049534732 @default.
• W4366824059 creator A5056603030 @default.
• W4366824059 creator A5057687478 @default.
• W4366824059 creator A5062259358 @default.
• W4366824059 creator A5071199467 @default.
• W4366824059 creator A5075910219 @default.
• W4366824059 creator A5076331208 @default.
• W4366824059 creator A5082063309 @default.
• W4366824059 creator A5082700645 @default.
• W4366824059 creator A5083296071 @default.
• W4366824059 creator A5085256859 @default.
• W4366824059 creator A5086810724 @default.
• W4366824059 creator A5087888043 @default.
• W4366824059 date "2023-04-24" @default.
• W4366824059 modified "2023-10-18" @default.
• W4366824059 title "Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial" @default.
• W4366824059 cites W1268992491 @default.
• W4366824059 cites W1491450727 @default.
• W4366824059 cites W1832926431 @default.
• W4366824059 cites W1847168837 @default.
• W4366824059 cites W1893543180 @default.
• W4366824059 cites W1968937229 @default.
• W4366824059 cites W1981662243 @default.
• W4366824059 cites W1988037885 @default.
• W4366824059 cites W1993023011 @default.
• W4366824059 cites W1995202691 @default.
• W4366824059 cites W2008854521 @default.
• W4366824059 cites W2015484447 @default.
• W4366824059 cites W2022532556 @default.
• W4366824059 cites W2025152196 @default.
• W4366824059 cites W2030316944 @default.
• W4366824059 cites W2030317956 @default.
• W4366824059 cites W2030602441 @default.
• W4366824059 cites W2037347658 @default.
• W4366824059 cites W2039384491 @default.
• W4366824059 cites W2053460912 @default.
• W4366824059 cites W2055453151 @default.
• W4366824059 cites W2058161128 @default.
• W4366824059 cites W2063808031 @default.
• W4366824059 cites W2076333797 @default.
• W4366824059 cites W2082429191 @default.
• W4366824059 cites W2113588440 @default.
• W4366824059 cites W2115017507 @default.
• W4366824059 cites W2119197968 @default.
• W4366824059 cites W2130886644 @default.
• W4366824059 cites W2131040457 @default.
• W4366824059 cites W2138485921 @default.
• W4366824059 cites W2142406431 @default.
• W4366824059 cites W2148080316 @default.
• W4366824059 cites W2150999725 @default.
• W4366824059 cites W2164546192 @default.
• W4366824059 cites W2167311298 @default.
• W4366824059 cites W2172969782 @default.
• W4366824059 cites W2177739274 @default.
• W4366824059 cites W2215407066 @default.
• W4366824059 cites W2289661106 @default.
• W4366824059 cites W2406449858 @default.
• W4366824059 cites W2582524520 @default.
• W4366824059 cites W2582711285 @default.
• W4366824059 cites W2590276210 @default.
• W4366824059 cites W2596674235 @default.
• W4366824059 cites W2618395897 @default.
• W4366824059 cites W2691085783 @default.
• W4366824059 cites W2794390181 @default.
• W4366824059 cites W2798054687 @default.
• W4366824059 cites W2800998714 @default.
• W4366824059 cites W2885996533 @default.
• W4366824059 cites W2896430225 @default.
• W4366824059 cites W2948815538 @default.
• W4366824059 cites W3021316273 @default.
• W4366824059 cites W3040840440 @default.
• W4366824059 cites W3107979799 @default.
• W4366824059 cites W3111509171 @default.
• W4366824059 cites W4210584483 @default.
• W4366824059 cites W4210987525 @default.
• W4366824059 cites W4211238543 @default.
• W4366824059 cites W4235875658 @default.
• W4366824059 cites W4282972828 @default.
• W4366824059 cites W4296698991 @default.
• W4366824059 cites W950120787 @default.
• W4366824059 doi "https://doi.org/10.1038/s41591-023-02326-3" @default.
• W4366824059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37095250" @default.

• next